CSBio CSBio

X
[{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health's Rifaximin Receives FDA Orphan Designation For Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Bausch Health"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"InMed Pharmaceuticals"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"InMed Pharmaceuticals"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"InMed Pharmaceuticals"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Case Western Reserve University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaTher"},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laurent Pharmaceuticals Presents Results from Phase 2 Clinical Study of LAU-7b in Cystic Fibrosis at the NACFC 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Laurent Pharmaceuticals"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaTher"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX\u2122 (Ketamine) for the Treatment of Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaTher"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Ketarx™(racemic ketamine), is a non-barbiturate, rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia diagnostic and surgical procedures typically in combination with a muscle relaxant.

            Lead Product(s): Ketamine Hydrochloride

            Therapeutic Area: Genetic Disease Product Name: Ketarx

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 03, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Ketalar (ketamine) is being developed rett syndrome, has the ability to increase cortical network activity, by selective inhibition of GABAergic interneurons as well as to decrease synaptic excitability in brainstem networks important for respiratory and autonomic control.

            Lead Product(s): Ketamine Hydrochloride

            Therapeutic Area: Genetic Disease Product Name: Ketalar

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 18, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            LAU-7b (oral fenretinide) is a novel candidate that acts on cell membrane lipids to modulate inflammation signaling and protein trafficking. Fenretinide was shown to correct the levels of certain membrane phospholipids and sphingolipids in multiple in vitro and in vivo models.

            Lead Product(s): Fenretinide

            Therapeutic Area: Genetic Disease Product Name: LAU-7b

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 03, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Ketamine (Ketalar), rapidly stimulates dendritic growth, BDNF levels, and expression of key synaptic proteins, at least in part through activation of mTOR signaling, which is deficient in Mecp2 mutants. Ketamine has shown the potential for treating Rett syndrome.

            Lead Product(s): Ketamine Hydrochloride

            Therapeutic Area: Genetic Disease Product Name: Ketalar

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Case Western Reserve University

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 01, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            In the peer-reviewed study, researchers analyzed the effects of rare INM-755 (cannabinol) THCV, CBC, cannabigerol (“CBG”) and cannabigerolic acid (“CBGA”) on the major endocannabinoid system elements in skin cells.

            Lead Product(s): Cannabinol

            Therapeutic Area: Genetic Disease Product Name: INM-755

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 14, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Company intends to use the net proceeds from the offerings to continue pipeline development including INM-755 (cannabinol), advance commercial activities and for general working capital purposes.

            Lead Product(s): Cannabinol

            Therapeutic Area: Genetic Disease Product Name: INM-755

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: H.C. Wainwright & Co.

            Deal Size: $5.0 million Upfront Cash: Undisclosed

            Deal Type: Private Placement June 06, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Company intends to use the net proceeds from the offerings to continue pipeline development including INM-755 having cannabinol, advance commercial activities and for general working capital purposes.

            Lead Product(s): Cannabinol

            Therapeutic Area: Genetic Disease Product Name: INM-755

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: H.C. Wainwright & Co.

            Deal Size: $5.0 million Upfront Cash: Undisclosed

            Deal Type: Private Placement June 02, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Company plans to start a Phase 2 trial in the first half of 2021 evaluating a novel rifaximin formulation for a potential sickle cell disease treatment.

            Lead Product(s): Rifaximin

            Therapeutic Area: Genetic Disease Product Name: Xifaxan

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 29, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY